Obstructive Sleep Apnea (OSA): History of Treatment Over Decades

The Pre-CPAP Era: Surgical Airway Bypass (1960s to Early 1980s)

Before clinicians had a name for obstructive sleep apnea, they had patients who stopped breathing at night and died. The first systematic description of the syndrome in the English-language literature came from Gastaut, Tassinari, and Duron in 1965, who documented repetitive apneas during polysomnography in patients with Pickwickian syndrome. [1] That paper reframed what had been dismissed as obesity-related somnolence into a discrete, measurable, potentially fatal airway disorder.

Tracheotomy as the Only Cure

With no pharmacologic or non-invasive option available, clinicians turned to the one intervention guaranteed to bypass the collapsible pharynx: tracheotomy. Kuhlo, Doll, and Franck reported in 1969 that permanent tracheostomy eliminated apneas and reversed the cardiac and neurological consequences they had observed in a series of severely affected patients. [2] For the next twelve years, tracheotomy remained the only proven curative treatment for severe OSA.

The procedure worked. It also carried substantial morbidity: stomal infections, tracheal stenosis, social stigma, and the psychological burden of a permanent neck opening. Acceptance was understandably low outside patients with life-threatening disease.

Polysomnography Defines the Disorder

The development of standardized overnight polysomnography in the 1970s gave clinicians the diagnostic language they needed. The apnea-hypopnea index (AHI) emerged as the primary severity metric. Guilleminault, Tilkian, and Dement's 1976 landmark paper in the Annual Review of Medicine formally described the sleep apnea syndromes and their cardiovascular sequelae, establishing the template for diagnostic criteria still used today. [3]

1981: The Year That Changed Everything

Two independent publications in 1981 redirected the entire field away from surgery.

Colin Sullivan and Nasal CPAP

On April 18, 1981, the Lancet published a five-patient case series by Colin Sullivan and colleagues at the University of Sydney. [4] The paper described a device that delivered room air at a fixed positive pressure through a tightly fitted nasal mask, acting as a pneumatic splint to maintain pharyngeal patency throughout the respiratory cycle. All five patients experienced complete elimination of apneas. The device was crude by modern standards, built from a reversed vacuum-cleaner motor, but the principle was sound and reproducible.

That single page-and-a-half letter is the founding document of modern OSA management.

UPPP Arrives Simultaneously

Shiro Fujita and colleagues published the uvulopalatopharyngoplasty (UPPP) procedure the same year, offering a surgical route to widening the velopharyngeal airway by excising redundant soft palate, uvula, and tonsillar tissue. [5] Early enthusiasm was high. Success rates, defined as greater than 50% AHI reduction, later proved to be closer to 40-50% in unselected patients, a figure confirmed by a 1996 meta-analysis in Sleep. Long-term data showed further deterioration in effect over time as soft tissue re-expanded.

The 1980s: CPAP Refinement and the First Adherence Crisis

The commercial CPAP devices available by the mid-1980s were heavy, noisy, and delivered fixed pressures that had been titrated manually during an attended polysomnography night. Mask interfaces were rudimentary. Many patients found the treatment intolerable and abandoned it within weeks.

Auto-Titrating CPAP

Auto-titrating positive airway pressure (APAP) devices arrived in the early 1990s to address fixed-pressure discomfort. These machines used flow and pressure-signal algorithms to detect apneas, hypopneas, and snoring in real time, raising and lowering delivered pressure breath by breath. A 2004 Cochrane review by Ayas et al. Confirmed that APAP achieved equivalent AHI control to fixed CPAP with modestly better patient-reported comfort scores. [6]

Bilevel PAP

Bilevel positive airway pressure (BiPAP) devices, delivering a higher inspiratory than expiratory pressure, were introduced commercially in 1990. They reduced the sensation of breathing against a constant pressure, improving comfort for patients who could not exhale comfortably on standard CPAP. Bilevel remained a second-line option in OSA until more sophisticated pressure-relief algorithms were embedded in standard CPAP machines.

Oral Appliances: A Dental-Sleep Medicine Collaboration (1980s to 1990s)

Mandibular advancement devices (MADs) protrude the lower jaw during sleep, mechanically widening the retroglossal airspace. The concept dates to the early 1980s, but clinical validation lagged until the 1990s.

AASM Endorsement and Evidence Base

The American Academy of Sleep Medicine's 1995 practice parameter report formally recognized oral appliances as a treatment option for mild-to-moderate OSA and for patients who refused or could not tolerate CPAP. [7] That document marked the moment dental sleep medicine became a recognized clinical subspecialty.

A 2015 Cochrane review by Lim, Lasserson, Fleetham, and Cole analyzed 67 trials and concluded that mandibular advancement devices reduced AHI significantly compared with no treatment, though less than CPAP. [8] Patient adherence to oral appliances consistently exceeded CPAP adherence in head-to-head comparisons, producing comparable improvements in daytime sleepiness despite inferior polysomnographic outcomes. The AASM and American Academy of Dental Sleep Medicine issued a joint clinical practice guideline in 2015 recommending oral appliances as an alternative when CPAP is not tolerated. [9]

Tongue Retaining Devices

Tongue-retaining devices, which hold the tongue forward via a suction bulb rather than advancing the mandible, represent a smaller niche within oral appliance therapy. They suit patients with temporomandibular joint disease who cannot tolerate jaw advancement. Evidence remains limited to small uncontrolled series.

Surgical Advances: Targeting the Anatomy (1990s to 2010s)

The recognition that pharyngeal collapse occurs at multiple anatomic levels drove the development of more targeted surgical procedures.

Upper Airway Stimulation

The most significant surgical advance in decades arrived with hypoglossal nerve stimulation (HNS), a fully implanted neurostimulation system that activates the genioglossus muscle during inspiration, restoring tongue protrusion and preventing retroglossal collapse. The STAR trial, published in the New England Journal of Medicine in 2014, enrolled 126 patients with moderate-to-severe OSA who had failed CPAP. [10] At 12 months, the median AHI fell from 29.3 to 9.0 events per hour (P<0.001), and 66% of participants met the composite responder criterion. The FDA approved the Inspire Upper Airway Stimulation system in April 2014.

Maxillomandibular Advancement

Maxillomandibular advancement (MMA) surgery advances the entire midface and mandible by 10 millimeters or more, permanently enlarging the bony framework housing the pharynx. Surgical success rates exceeding 85-90% have been reported in appropriately selected patients, making MMA the most anatomically effective surgical option, though its invasiveness limits uptake. A 2010 review by Zaghi and colleagues in the International Journal of Oral and Maxillofacial Surgery compiled outcomes across 627 cases. [11]

Targeted Soft Tissue Procedures

Isolated UPPP gave way to multi-level surgical protocols combining palatal surgery with tongue-base procedures, inferior turbinate reduction, or nasal reconstruction. The Stanford protocol, developed by Powell and Riley, systematically addressed obstructions from nose to hypopharynx in a staged approach. Objective response rates improved compared with UPPP alone, though randomized controlled trial data remained sparse.

Positional Therapy and Behavioral Interventions

Roughly 56% of OSA patients have position-dependent disease, with AHI at least twice as high in the supine position. Positional therapy, ranging from the tennis-ball technique (sewing a ball into the back of a sleep shirt) to commercially available vibrotactile devices, addresses this subset.

A 2012 study published in Sleep found that a vibrotactile positional device reduced supine sleep time from 53% to 8% of total sleep time and reduced AHI from 22.4 to 12.8 events per hour in position-dependent patients. [12] Positional therapy is currently recommended by the AASM as an adjunct rather than a standalone treatment for most patients.

Weight loss has been recognized as an OSA modifier since the syndrome was first described. A 10% weight reduction produces roughly a 26% reduction in AHI, per a dose-response analysis by Peppard and colleagues in JAMA Internal Medicine in 2000. [13] The challenge was that sustained weight loss sufficient to meaningfully alter OSA severity was rarely achieved through lifestyle intervention alone.

The Pharmacologic Era Begins (2010s to Present)

For most of its clinical history, OSA had no approved pharmacologic treatment. Modafinil and armodafinil received FDA approval for residual excessive daytime sleepiness in CPAP-treated patients in 1998 and 2007 respectively, but neither addressed the underlying airway disorder. [14]

GLP-1 Receptor Agonists and OSA

The arrival of highly effective weight-loss pharmacotherapy changed the therapeutic calculus fundamentally. Semaglutide 2.4 mg weekly (Wegovy) produced 14.9% mean body weight reduction at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% with placebo. [15] Because OSA severity tracks closely with adiposity, investigators hypothesized that GLP-1-class agents might reduce AHI clinically.

The SURMOUNT-OSA trial tested this hypothesis directly. The study enrolled 469 adults with moderate-to-severe OSA and obesity. Participants randomized to tirzepatide 10 or 15 mg weekly achieved a mean AHI reduction of approximately 55% from baseline at 52 weeks, compared with roughly 5% in the placebo group. [16] Body weight fell by a mean of 17.7% in the tirzepatide arm.

FDA Approval of Tirzepatide for OSA

On December 20, 2024, the FDA approved tirzepatide injection (Zepbound, Eli Lilly) specifically for treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, making it the first drug ever approved for this indication in the United States. [17] The prescribing information specifies use in conjunction with a reduced-calorie diet and increased physical activity. The label does not position tirzepatide as a replacement for CPAP; rather, it addresses the weight-driven anatomical component of OSA.

The HealthRX medical team proposes the following decision framework for integrating pharmacologic weight loss into OSA care. Clinicians should classify patients into three groups based on CPAP adherence and BMI at baseline: (1) CPAP-adherent patients with BMI ≥30 who retain residual disease may add a GLP-1/GIP agent to reduce anatomical load; (2) CPAP-intolerant patients with BMI ≥30 may trial pharmacologic therapy as a primary strategy while pursuing alternative PAP modes or oral appliances; (3) patients with BMI <30 and anatomically driven OSA remain candidates for surgical or device-based therapy regardless of GLP-1 eligibility. This framework will be refined as longer-term SURMOUNT-OSA extension data become available.

CPAP Technology Evolution: From Fixed Pressure to Connected Care

The CPAP machine of 2025 shares little beyond the core pneumatic principle with Sullivan's 1981 prototype. Modern devices weigh under one kilogram, produce fewer than 26 decibels of noise, and deliver pressure-relief algorithms (such as Philips Respironics C-Flex and ResMed EPR) that soften the expiratory pressure load.

Heated Humidification

Heated humidification, now standard on virtually all devices, reduced mucosal dryness and nasal congestion, which had been leading drivers of CPAP abandonment in the 1990s. A randomized crossover trial by Rakotonanahary et al. Published in Chest in 2001 showed that adding heated humidification increased CPAP adherence by a mean of 0.8 hours per night over 4 weeks. [18]

Remote Monitoring and Telemedicine

Cloud-connected CPAP devices, deployed widely by 2015, transmit nightly AHI, mask leak, and usage data to clinician dashboards in real time. A 2018 randomized controlled trial in the Journal of Clinical Sleep Medicine found that web-based adherence monitoring with automated patient feedback improved 90-day CPAP adherence by 1.1 hours per night compared with standard care. [19]

Adaptive Servo-Ventilation

Adaptive servo-ventilation (ASV) devices, designed for complex sleep-disordered breathing including central apneas and Cheyne-Stokes respiration, use a servo-controlled algorithm to deliver variable pressure support based on recent breath-by-breath ventilatory data. The SERVE-HF trial, published in the New England Journal of Medicine in 2015, found increased all-cause and cardiovascular mortality with ASV in patients with heart failure with reduced ejection fraction and predominant central sleep apnea, leading to a labeled contraindication in that population. [20] ASV remains appropriate for other complex breathing patterns.

Pediatric OSA: A Parallel Treatment History

Adenotonsillectomy has been the primary treatment for pediatric OSA since the 1970s, predating CPAP by a decade. The CHAT trial, published in the New England Journal of Medicine in 2013 (N=464), found that early adenotonsillectomy produced greater improvement in polysomnographic outcomes, behavior, and quality of life at 7 months compared with watchful waiting, though AHI normalized in a substantial minority of the observation group as well. [21] CPAP is recommended for pediatric patients who fail or are not candidates for adenotonsillectomy, per the American Academy of Pediatrics. [22]

Current Guidelines: Where the Evidence Stands

The AASM 2019 clinical practice guideline for the treatment of OSA in adults provides the strongest current summary of the evidence base. [23] Key recommendations include:

• CPAP is recommended over no therapy (strong recommendation, high-quality evidence).
• Oral appliances are recommended for patients who prefer them over CPAP or cannot tolerate CPAP (strong recommendation, moderate-quality evidence).
• Surgical therapy is recommended only after failure of PAP and oral appliance therapy, except in patients with specific anatomic abnormalities amenable to surgery.
• Weight-loss interventions, including behavioral, pharmacologic, and surgical approaches, are recommended as adjunct rather than primary therapy.

The American Heart Association's 2021 scientific statement on sleep and cardiovascular health noted that OSA is independently associated with hypertension, atrial fibrillation, and incident cardiovascular disease, reinforcing the importance of treatment beyond symptom management. [24]

As of the guideline's 2019 publication, approximately 936 million adults worldwide met diagnostic criteria for OSA, with only a minority diagnosed or treated, per Benjafield and colleagues in Lancet Respiratory Medicine. [25]